StockData

Amgen vs Gilead Sciences

AMGN and GILD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMGN and GILD compare

Amgen is the larger company, worth 1.2 times as much as Gilead Sciences ($252B against $208B).

Amgen grew revenue faster over the last twelve months (8.2% versus 6.5% for Gilead Sciences).

Amgen keeps more of each dollar of sales as profit, with a net margin of 24.1% compared with −12.5% at Gilead Sciences.

Both pay dividends: Amgen yields 2.1% and Gilead Sciences 1.9%.

Amgen scores higher on the StockData Score (17 against 11 for Gilead Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMGNGILD
Size and price
Market cap$252B$208B
Share price$465.67$168.08
Change, 1 year38.5%36.2%
Change, 5 years126%145%
Beta (5Y)0.410.43
Employees32K17K
StockData Score
Total score17 (better)11
Valuation score00
Growth score5 (better)2
Performance score6 (better)3
Health score23 (better)
Dividend score4 (better)3
Valuation
P/E27.0×–
P/S6.5× (better)6.7×
P/B17.5×16.0× (better)
EV/EBITDA19.1×–
P/FCF26.3×15.1× (better)
PEG4.89–
FCF yield3.8%6.6% (better)
Fair value$380.41$82.37
Margin of safety−22.4% (better)−104%
Growth
Revenue growth (TTM)8.2% (better)6.5%
Revenue growth, 5Y average7.6% (better)3.6%
Net income growth (TTM)34.1% (better)−148%
EPS growth (TTM)33.3% (better)−149%
EPS growth, 5Y average2.9%132% (better)
Profitability
Gross margin70.9%79.9% (better)
Operating margin32.4% (better)−7.6%
Net margin24.1% (better)−12.5%
FCF margin24.6%44.5% (better)
Return on equity78.4% (better)−22.3%
Return on invested capital19.5% (better)−5.2%
Financial health
Debt / equity3.762.01 (better)
Net debt / EBITDA2.67–
Interest coverage4.8× (better)−2.3×
Current ratio1.48 (better)1.38
Altman Z-score2.543.89 (better)
Piotroski F-score78 (better)
Dividends and buybacks
Dividend yield2.1% (better)1.9%
Payout ratio57.1%–
Years of dividend growth911 (better)
Dividend growth, 5Y average8.0% (better)3.0%
Buyback yield–0.52%
Shareholder yield2.1%2.5% (better)
Ownership
Held by institutions82.7%89.8%
Held by insiders0.21%0.10%
Insider net buying, 12 months−$25.7M (better)−$99.2M
Short interest, % of float2.3%1.7%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.